The Rock

2023 - 2 - 6

Post cover — Image courtesy of "ojaivalleynews.com"

Ojai Valley News Events - Fifty and Better Winter Session: Rock ... (ojaivalleynews.com)

American Popular music was in the midst of an historic change in the mid-1950's. While many of the artists and songs central to this music revolution hailed ...

Don't pick up Bretman Rock's new memoir, 'You're That Bitch' (The Michigan Daily)

Bretman Rock is a force to be reckoned with, but his memoir is something that should go unnoticed and unread.

From inserts on “Douching Your Ass Like a Bad Bitch” to “How to Deal with Bullies” and “Finding Connection,” the planned readership is unclear. I won’t lie and say there wasn’t anything I enjoyed about “You’re That Bitch.” Highlights of the memoir were Rock’s efforts to make the reader laugh, with lines like “Walmart was the birthplace of my essence,” and when he declared Junie B. Unfortunately, “You’re That Bitch” is not a book I would — or could — recommend. Beyond simple spelling and grammatical errors — I’m not talking about purposeful errors, like the fact that Rock manages to spell “sexy” three different ways on the same page, but errors that had me checking to see if I received an uncorrected proof — the memoir’s structure is falling apart at the seams, the organization is almost laughable. “I’ve always been a divine blend of masculine and feminine—so if I look like a lesbian after a bicep bulging workout, call me he, but if I’m in full makeup wearing a Catholic schoolgirl plaid skirt and barrettes, call me she,” Rock wrote in the introduction. Since “he/him/his” pronouns are used in his biography and in the book jacket blurb, those are the pronouns I will use throughout this review.

Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer (Business Wire)

Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth f.

For more information, please visit [www.ScholarRock.com](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DyPG71har4BelARSQ4fVL9FM3jgal2bGy9sR8OjyxCsA-036cSx8B57ygv94NVpG3DVb6EP5QXdNUWEQ46Ko1HoQitASHSTmD9HTP4sP0Qsk%3D&esheet=53298624&newsitemid=20230206005061&lan=en-US&anchor=www.ScholarRock.com&index=3&md5=7296c17388818568ae8ce6cd50eeb1a8) or follow Scholar Rock on Twitter ( [@ScholarRock](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftwitter.com%2FScholarRock&esheet=53298624&newsitemid=20230206005061&lan=en-US&anchor=%40ScholarRock&index=4&md5=e275f0a86a7615eb9653b21b619f4ed3)) and LinkedIn ( [https://www.linkedin.com/company/scholar-rock/](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fscholar-rock%2F&esheet=53298624&newsitemid=20230206005061&lan=en-US&anchor=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fscholar-rock%2F&index=5&md5=97eaec0ff0dfa50a034eea8fd57c3d41)). All information in this press release is as of the date of the release, and Scholar Rock undertakes no duty to update this information unless required by law. This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar Rock’s future expectations, plans and prospects, including without limitation, Scholar Rock’s expectations regarding its growth, strategy, progress and timing of its clinical trials for apitegromab, SRK-181, and other product candidates and indication selection and development timing, the ability of any individual to affect the performance of the company, the ability of any product candidate to perform in humans in a manner consistent with earlier nonclinical, preclinical or clinical trial data, and the potential of its product candidates and proprietary platform. These risks and uncertainties include, without limitation, that preclinical and clinical data, including the results from the Phase 2 clinical trial of apitegromab, or Part A of the Phase 1 clinical trial of SRK-181, are not predictive of, may be inconsistent with, or more favorable than, data generated from future clinical trials of the same product candidate, including, without limitation, the Phase 3 clinical trial of apitegromab in SMA or Part B of the Phase 1 clinical trial of SRK-181, Scholar Rock’s ability to provide the financial support, resources and expertise necessary to identify and develop product candidates on the expected timeline, the data generated from Scholar Rock’s nonclinical and preclinical studies and clinical trials, information provided or decisions made by regulatory authorities, competition from third parties that are developing products for similar uses, Scholar Rock’s ability to obtain, maintain and protect its intellectual property, Scholar Rock’s dependence on third parties for development and manufacture of product candidates including, without limitation, to supply any clinical trials, Scholar Rock’s ability to manage expenses and to obtain additional funding when needed to support its business activities and establish and maintain strategic business alliances and new business initiatives, and the impacts of public health pandemics such as COVID-19 on business operations and expectations, as well as those risks more fully discussed in the section entitled "Risk Factors" in Scholar Rock’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock’s subsequent filings with the Securities and Exchange Commission. I’m thrilled to be joining the Scholar Rock team at a time with so much positive momentum and look forward to contributing to the success of the apitegromab program by preparing for the company’s first commercial launch,” said Ms. “Tracey is an exceptional leader with a proven track record of building commercial organizations and launching new products in the rare disease area. “Scholar Rock has developed a differentiated and a validated scientific approach to addressing devastating illnesses and has the potential to bring truly practice-changing medicines to patients. The information that we post on our website or on Twitter or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. from NYU Stern School of Business and a B.A. “Our ongoing Phase 3 SAPPHIRE trial is our top priority, and we are committed to the patients who we believe may benefit from apitegromab. [BUSINESS WIRE](https://www.businesswire.com/))--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Tracey M.

Chris Rock Through the Years: 'SNL,' Oscars Slap and More (Us Weekly)

Chris Rock became an A-lister in Hollywood after being cast on 'Saturday Night Live' in the '90s — see his career in photos.

(The former couple were married from 1996 to 2016 and share two daughters.) Smith subsequently gave up his membership to the Academy of Motion Picture Arts and Sciences and was [banned from Oscars-related events](https://www.usmagazine.com/celebrity-news/news/will-smith-reacts-to-academy-ban-after-chris-rock-oscars-slap/) for 10 years. “Getting divorced, you have to f–king start over,” he said. He remained on the series until 1993 and has since [ returned to host the late-night show](https://www.usmagazine.com/entertainment/pictures/snl-stars-who-landed-a-list-romances-pics/) multiple times over the years. [he’d toned down his remarks about marriage](https://www.usmagazine.com/celebrity-news/news/chris-rock-recommended-his-ex-wifes-divorce-lawyer-to-john-mulaney/) in his stand-up shows at the time. In a 2017 Rolling Stone interview, the Grown Ups actor got candid about Rock added that he simply “shook that s–t off” and got back to work. (Smith later returned to the audience and warned, “Keep my wife’s name out your f–king mouth.”) “Yeah, that s–t hurt, motherf–ker. “Anyone who says words hurt has never been punched in the face,” he teased during a July 2022 performance in New Jersey. “I’m not a victim, motherf–ker,” he told the crowd. “SNL is still a pretty white show,” Rock recalled during an interview on “WTF With Marc Maron” in 2011.

“The Rock” Endured a Brutal Giant Sets Leg Workout, Ending With ... (generationiron.com)

"The Rock" underwent a brutal leg workout utilizing giant sets and ending it with belted squats. Click the link to see the benefits!

They also don’t activate your [glutes](https://generationiron.com/8-exercises-building-glutes/) to the same extent. [belt ](https://generationiron.com/best-weightlifting-belts/)to support the weight. Then stand in front of the machine and strap the belt attached to the machine around your waist. Doing squats on a machine is the safer alternative to barbell squats and gives your body another angle to work with and shock your body. Belted squats are perfect lower-body exercises to build strength and power while placing less strain on your body. And recently, he went to Instagram to upload a short clip of the ending of his brutal leg workout filled with giant sets. It was important for WWE and has landed him big roles to configure into an action-figure icon on the silver screen. For example, you can giant set dumbbell goblet squats (legs), As standard squats, belted squats are a good [lower body](https://generationiron.com/essential-lower-body-exercises/) movement that targets your glutes, [hamstrings](https://generationiron.com/4-exercises-build-hamstrings/), and quads. The belted squats don’t engage your Dwayne “The Rock” Johnson is one of the most prominent A-list celebrities in the world. He did giant sets (we’ll dive into later) and ended his workout with 15-20 reps of belt squats.

Las Vegas Strip Welcomes Back Huge Rock Legend (TheStreet)

The Las Vegas Strip offers a variety of entertainment on stage, including magic acts, comedians and big name music performances.